AstraZeneca and China International Capital to launch $1 bln China biotech venture fund: Bloomberg


U.S. drugmaker AstraZeneca and China International Capital Corp are teaming up to launch a $1 billion China-focused biotech venture fund, reported Bloomberg. The news outlet added that AstraZeneca will not be a majority investor, according to CEO Pascal Soriot.